Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE2
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
- Status
- COMPLETED
- Phase
- PHASE2